Advanced Molecular Diagnosis and Treatment of Biliary Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 7
Special Issue Editor
Interests: molecular mechanisms elucidation and discovery of new therapeutic strategies for cancers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue, "Advanced Molecular Diagnosis and Treatment of Biliary Cancer," is dedicated to showcasing the transformative advances in understanding and managing this aggressive group of malignancies. Once characterized by a limited therapeutic landscape, biliary cancer is now being redefined by its complex molecular heterogeneity. The identification of distinct molecular subtypes driven by alterations such as FGFR2 fusions, IDH1 mutations, HER2 amplifications, microsatellite instability, and epigenetic aberrations has opened a new era of precision oncology. This issue will compile original research and comprehensive reviews that explore the development of novel biomarkers, the clinical utility of advanced diagnostic methods, and the efficacy of both existing and innovative therapies tailored to these molecular drivers. By bridging cutting-edge molecular diagnostics with emerging therapeutic strategies, this collection aims to illuminate the path toward personalized medicine, ultimately improving survival and quality of life for patients worldwide.
Dr. Jing Han Hong
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biliary tract cancer
- cholangiocarcinoma
- epigenetics
- rare cancers
- molecular characterisation
- precision medicine
- drug development
- molecular heterogeneity
- precision oncology
- therapy
- biomarkers
- diagnosis
- molecular mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
